نتائج البحث

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M حسب Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard

احصل على النص الكامل

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma حسب Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi

احصل على النص الكامل احصل على النص الكامل

<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer حسب Toshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, Junko Hamamoto, Ayano Oashi, Kota Ishioka, Daisuke Arai, Shigenari Nukaga, Masayoshi Miyawaki, Ichiro Kawada, Katsuhiko Naoki, Daniel B. Costa, Susumu Kobayashi, Tomoko Betsuyaku, Kenzo Soejima

احصل على النص الكامل احصل على النص الكامل

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients حسب David Planchard, Yohann Loriot, Fabrice André, A. Gobert, Nathalie Auger, Ludovic Lacroix, Jean‐Charles Soria

احصل على النص الكامل احصل على النص الكامل

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors حسب Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson

احصل على النص الكامل

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas حسب Alexis B. Cortot, Pasi A. Jänne

احصل على النص الكامل

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1 حسب Valentina Pirazzoli, Caroline A. Nebhan, Xiaoling Song, Anna Wurtz, Zenta Walther, Guoping Cai, Zhongming Zhao, Peilin Jia, Elisa de Stanchina, Erik M. Shapiro, Molly Gale, Ruonan Yin, Leora Horn, David P. Carbone, Philip J. Stephens, Vincent A. Miller, Scott Gettinger, William Pao, Katerina Politi

احصل على النص الكامل احصل على النص الكامل

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping حسب Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

احصل على النص الكامل احصل على النص الكامل

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer حسب Lucía Regales, Yixuan Gong, Ronglai Shen, Elisa de Stanchina, Igor Vivanco, Aviva Goel, Jason A. Koutcher, Maria Spassova, Ouathek Ouerfelli, Ingo K. Mellinghoff, Maureen F. Zakowski, Katerina Politi, William Pao

احصل على النص الكامل

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET حسب Lu Xu, Eiki Kikuchi, Chunxiao Xu, Hiromichi Ebi, Dalia Ercan, Katherine A. Cheng, Robert F. Padera, Jeffrey A. Engelman, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura, Kwok‐Kin Wong

احصل على النص الكامل

Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer حسب Takeshi Yoshida, Guolin Zhang, Eric B. Haura

احصل على النص الكامل

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC حسب Mark Agulnik, Nelson, Ziehr, J R Johnson

احصل على النص الكامل احصل على النص الكامل

<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib حسب James Bean, Cameron Brennan, Jin‐Yuan Shih, Gregory J. Riely, Agnès Viale, Lu Wang, Dhananjay Chitale, Noriko Motoi, János Szőke, Stephen Broderick, Marissa N. Balak, W.C. Chang, Chong‐Jen Yu, Adi F. Gazdar, Harvey I. Pass, Valerie W. Rusch, William L. Gerald, Shiu‐Feng Huang, Pan‐Chyr Yang, Vincent A. Miller, Marc Ladanyi, James Chih‐Hsin Yang, William Pao

احصل على النص الكامل

Double <i>EGFR</i> mutants containing rare <i>EGFR</i> mutant types show reduced <i>in vitro</i> response to gefitinib compared with common activating missense mutations حسب Issan Yee San Tam, Elaine Lai‐Han Leung, Vicky Pui‐Chi Tin, Daniel Chua, Alan Dart‐Loon Sihoe, Lik‐Cheung Cheng, Lap-Ping Chung, Maria P. Wong

احصل على النص الكامل احصل على النص الكامل

Activation of IL-6R/JAK1/STAT3 Signaling Induces <i>De Novo</i> Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation حسب Sun Mi Kim, Oh-Joon Kwon, Yun Hong, Joo Hang Kim, Flavio Solca, Sang‐Jun Ha, Ross A. Soo, James G. Christensen, Ji Hyun Lee, Byoung Chul Cho

احصل على النص الكامل احصل على النص الكامل

The<i>EGFR</i>T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor حسب Young-Wook Kim, Jeong‐Hun Ko, Zheng-Yun Cui, Amir Abolhoda, Jin Seok Ahn, Sai-Hong Ou, Myung‐Ju Ahn, Keunchil Park

احصل على النص الكامل احصل على النص الكامل

Pretreatment Epidermal Growth Factor Receptor (<i>EGFR</i>) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Ca... حسب Kang‐Yi Su, Hsuan‐Yu Chen, Ker-Chau Li, Min‐Liang Kuo, James Chih‐Hsin Yang, Wing‐Kai Chan, Bing‐Ching Ho, Gee‐Chen Chang, Jin‐Yuan Shih, Sung‐Liang Yu, Pan‐Chyr Yang

احصل على النص الكامل احصل على النص الكامل

Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation حسب Tatsuya Yoshida, Genichiro Ishii, Kōichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Shinsuke Iida, Akio Niimi, Kanji Nagai, Yuichiro Ohe, Atsushi Ochiai

احصل على النص الكامل

Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors حسب Helena A. Yu, Gregory J. Riely, Christine M. Lovly

احصل على النص الكامل احصل على النص الكامل

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib حسب Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller

احصل على النص الكامل احصل على النص الكامل